General and Administrative (G&A) Expenses: G&A expenses were $9.7 million for the quarter ended March 31, 2025, compared to $10.3 million for the quarter ended March 31, 2024. The decrease was ...

Presented new preclinical data for OP-3136 at the American Association for Cancer Research (AACR) Annual Meeting in April, demonstrating anti-tumor activity in pre-clinical in vitro and in vivo ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and ...

Good afternoon, everyone and thank you for joining our conference call to discuss BioStem Technologies' first quarter 2025 financial results and corporate highlights. Leading the call today will be ...

FDA Clearance of Catamaran® SI Joint Fusion System for New Indication to Augment Spinal Fusion ~~ Catamaran® SI Joint Fusion Technology Protected with Robust Patent Portfolio of Twelve U.S. and Intern ...

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...

Operator: Good day, ladies and gentlemen. Welcome to Assertio Holdings First Quarter 2025 Results Conference Call. Just a ...

Group's First Quarter 2025 Conference Call and Webcast. At this time, all participants have been placed in a listen-only mode. It is now my pleasure to turn the floor over to Matt Kreps, Investor ...

Anthony Edwards scored 30 points for his second straight 30-point performance, Julius Randle had 31 points and the Minnesota ...

To avoid being charged the recurring subscription fee, simply cancel before the free-trial period ends - it’s just $4.99/mo afterward. *To avoid being charged the recurring subscription fee ...

Total Liabilities Shareholders' Equity 4,80,196.57 4,47,913.25 4,24,945.90 3,98,887.64 ...